Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SOLESENCE, INC.NANX · Entity 7041 | Director · President, CEO | December 31, 2024 | January 13, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SOLESENCE, INC.
Report date December 31, 2024 · Filed January 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 · Expires 2031-12-31 | Direct | 22,500 |
Reported balance
After 2024-12-31 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-12-31 · Grant · Acquired 22,500 · Balance 22,500 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.42 · Expires 2026-02-23 | Direct | 69,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 69,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.68 · Expires 2027-02-21 | Direct | 81,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 81,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-05-23 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2029-05-22 | Direct | 16,500 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 16,500 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.45 · Expires 2027-06-18 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.17 · Expires 2028-12-28 | Direct | 90,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 90,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2029-12-20 | Direct | 72,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 72,000 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common Stock (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.61 · Expires 2030-12-27 | Direct | 12,600 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 12,600 F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. |
| Common StockSEC Table I · non-derivative | IndirectSpouse's IRA | 1,000 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,000 |
| Common StockSEC Table I · non-derivative | Direct | 207,450 |
Reported balance
Holding disclosure · report date 2024-12-31 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 207,450 |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,000 | $2.28 | $2,280.00 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,000 | $0.42 Strike: $0.42 | $415.00 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,017 Underlying: Common Stock · 75,017 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,000 | $2.28 | $2,280.00 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 04, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,000 | $0.42 | $415.00 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 03, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 4,283 | $0.42 Strike: $0.42 | $1,777.45 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · derivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,017 Underlying: Common Stock · 79,300 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 03, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 4,283 | $2.30 | $9,850.90 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 03, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 4,283 | $0.42 | $1,777.45 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 4,283 | $0.42 Strike: $0.42 | $1,777.45 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · derivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,017 Underlying: Common Stock · 79,300 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 4,283 | $2.30 | $9,850.90 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 4,283 | $0.42 | $1,777.45 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 02, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 7,400 | $0.42 Strike: $0.42 | $3,071.00 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · derivative · entry 9 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,300 Underlying: Common Stock · 86,700 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 02, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 7,400 | $2.42 | $17,908.00 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 02, 2022 Filed Nov 5, 2022 01:00 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 7,400 | $0.42 | $3,071.00 |
DisclosureSEC source: 0001209191-22-055875 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 02, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 7,400 | $0.42 Strike: $0.42 | $3,071.00 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · derivative · entry 9 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,300 Underlying: Common Stock · 86,700 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| November 02, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 7,400 | $2.42 | $17,908.00 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| November 02, 2022 Filed Nov 7, 2022 22:00 UTC Amendment | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 7,400 | $0.42 | $3,071.00 |
DisclosureSEC source: 0001209191-22-055965 · doc4a.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| October 25, 2022 Filed Oct 26, 2022 22:06 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 800 | $0.42 Strike: $0.42 | $332.00 |
DisclosureSEC source: 0001209191-22-054667 · doc4.xml · derivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,700 Underlying: Common Stock · 87,500 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| October 25, 2022 Filed Oct 26, 2022 22:06 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 800 | $2.34 | $1,872.00 |
DisclosureSEC source: 0001209191-22-054667 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| October 25, 2022 Filed Oct 26, 2022 22:06 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 800 | $0.42 | $332.00 |
DisclosureSEC source: 0001209191-22-054667 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 22:06 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 2,500 | $0.42 Strike: $0.42 | $1,037.50 |
DisclosureSEC source: 0001209191-22-054667 · doc4.xml · derivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,500 Underlying: Common Stock · 90,000 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski converted and sold these shares through a 10b5-1 Plan that has been established with an independent broker. His goal is to have this broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 22:06 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 2,500 | $2.35 | $5,875.00 |
DisclosureSEC source: 0001209191-22-054667 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| October 24, 2022 Filed Oct 26, 2022 22:06 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 2,500 | $0.42 | $1,037.50 |
DisclosureSEC source: 0001209191-22-054667 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. F1 · price: These stock options are set to expire on 02/14/2023. Mr. Jankowski established a 10b5-1 Plan with an independent broker with a goal of having his broker sell shares from this grant, under fixed guidleines, in a regular and measured manner designed to avoid both forfeiture of shares due to expiration, and impacting the stock price due to excessive trading volume. His Plan was approved in advance by the Compensation & Governance Committee of the Nanophase Board of Directors. Read SEC document |
| June 22, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 9,560 | $0.30 Strike: $0.30 | $2,868.00 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,560 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 22, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 9,560 | $2.78 | $26,576.80 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 22, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 9,560 | $0.30 | $2,868.00 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 9,000 | $0.30 Strike: $0.30 | $2,700.00 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · derivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,560 Underlying: Common Stock · 18,560 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 9,000 | $2.81 | $25,290.00 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 21, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 9,000 | $0.30 | $2,700.00 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 25,000 | $0.30 Strike: $0.30 | $7,500.00 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · derivative · entry 9 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,560 Underlying: Common Stock · 43,560 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 25,000 | $2.86 | $71,500.00 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 22:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 25,000 | $0.30 | $7,500.00 |
DisclosureSEC source: 0001209191-22-038759 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. F1 · price: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:01 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 12,485 | $0.30 Strike: $0.30 | $3,745.50 |
DisclosureSEC source: 0001209191-22-037945 · doc4.xml · derivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,560 Underlying: Common Stock · 56,045 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:01 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 12,485 | $3.00 | $37,455.00 |
DisclosureSEC source: 0001209191-22-037945 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:01 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 12,485 | $0.30 | $3,745.50 |
DisclosureSEC source: 0001209191-22-037945 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 13, 2022 Filed Jun 17, 2022 21:01 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 7,800 | $0.30 Strike: $0.30 | $2,340.00 |
DisclosureSEC source: 0001209191-22-037945 · doc4.xml · derivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,045 Underlying: Common Stock · 63,845 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. F3 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| June 13, 2022 Filed Jun 17, 2022 21:01 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 7,800 | $3.00 | $23,400.00 |
DisclosureSEC source: 0001209191-22-037945 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 13, 2022 Filed Jun 17, 2022 21:01 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 7,800 | $0.30 | $2,340.00 |
DisclosureSEC source: 0001209191-22-037945 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This transaction was communicated to the reporting person on June 17th due to a clerical error. F2 · price: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 21,100 | $0.30 Strike: $0.30 | $6,330.00 |
DisclosureSEC source: 0001209191-22-036393 · doc4.xml · derivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,845 Underlying: Common Stock · 84,945 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. F2 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 21,100 | $3.01 | $63,511.00 |
DisclosureSEC source: 0001209191-22-036393 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 21:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 21,100 | $0.30 | $6,330.00 |
DisclosureSEC source: 0001209191-22-036393 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 1,500 | $0.30 Strike: $0.30 | $450.00 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · derivative · entry 11 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,945 Underlying: Common Stock · 86,445 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. F2 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 1,500 | $3.00 | $4,500.00 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · nonDerivative · entry 8 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 1,500 | $0.30 | $450.00 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · nonDerivative · entry 7 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 100 | $0.30 Strike: $0.30 | $30.00 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · derivative · entry 10 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. F2 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 100 | $3.00 | $300.00 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · nonDerivative · entry 6 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 100 | $0.30 | $30.00 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · nonDerivative · entry 5 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock (right to purchase) · Derivative | 11,455 | $0.30 Strike: $0.30 | $3,436.50 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · derivative · entry 9 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,455 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. F2 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | SaleCommon Stock | 11,455 | $3.03 | $34,708.65 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · nonDerivative · entry 4 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,000 Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 22:16 UTC | SOLESENCE, INC. NANX · Entity 7041 | Exercise / conversionCommon Stock | 11,455 | $0.30 | $3,436.50 |
DisclosureSEC source: 0001209191-22-035173 · doc4.xml · nonDerivative · entry 3 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These options were set to expire on 08/07/2022. Under the Company's Policy on Insider Trading, all Nanophase employees will enter a blackout period on 06/25/2022, which will not end until three working days after the Company releases Q22022 earnings. Read SEC document |
| December 28, 2021 Filed Dec 30, 2021 17:43 UTC | SOLESENCE, INC. NANX · Entity 7041 | GrantCommon Stock (right to purchase) · Derivative | 90,000 | $4.17 Strike: $4.17 | $375,300.00 |
DisclosureSEC source: 0001209191-21-071578 · doc4.xml · derivative · entry 12 JANKOWSKI JESS · CIK 0001184478 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2028-12-28 F2 · derivative.exercise_date: Subject to certain restrictions, beginning on this date, options vest in three equal installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.